Biomarkers of Isolated Coronary Arteritis and Related Pathogenic Mechanism

N

National Center for Cardiovascular Diseases

Status

Enrolling

Conditions

Arteritis
Coronary Artery Disease

Treatments

Drug: glucocorticoid and immunosuppressants

Study type

Observational

Funder types

Other

Identifiers

NCT05437965
2021-ZX50

Details and patient eligibility

About

The design of this study is generally divided into two parts: First, establish an isolated coronary arteritis cohort. Then, through the case-control study, the clinical characteristics of patients with isolated coronary arteritis and patients with coronary artery disease are compared and the preliminary screening criteria for patients are constructed. Then, through mass spectrometry flow cytometry and cytokine detection, the biomarkers related to immune inflammation related to the occurrence of coronary artery disease are discussed to provide clues for further exploring the pathogenesis; Subsequently, a prospective cohort study was conducted to compare the clinical characteristics and biomarkers of patients with or without adverse cardiovascular events by following up patients with coronary inflammation, and to explore the prognostic factors of patients with coronary inflammation.

Enrollment

248 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

isolated coronary arteritis group inclusion criteria Age ≥ 18 and ≤ 75; Patients with coronary heart disease, complete revascularization, standardized medication, and repeated hospitalization for myocardial infarction or ischemia within 1 year. Coronary angiography showed coronary artery stenosis or occlusion. The patient (or legal guardian) is fully informed of the test process and signs the informed consent form. coronary artery disease group inclusion criteria Age ≥ 18 and ≤ 75; Patients with coronary heart disease (at least one vessel underwent coronary stent implantation) and regular medication. No hospitalization with myocardial infarction or ischemia drive occurred within 1 year. The patient (or legal guardian) is fully informed of the test process and signs the informed consent form.

Exclusion criteria

The patient has the following conditions: Have other serious diseases (malignant tumor, heart failure, etc.), and the life expectancy is less than 12 months; The patient has known rheumatic immune diseases such as systemic lupus erythematosus, Takayasu arteritis, Behcet's disease, nodular polyarteritis, Wegener granuloma, eosinophil arteritis, giant cell arteritis, rheumatoid arthritis and immunoglobulin G4 related diseases; Variant angina pectoris; Coronary artery dissection; Thrombophilia; Incomplete expansion of stent; Mental illness; Failure to complete the expected study follow-up for any known reason; The investigator judged that it was not suitable for the enrolled patients.

Trial design

248 participants in 2 patient groups

isolated coronary arteritis
Treatment:
Drug: glucocorticoid and immunosuppressants
coronary artery disease

Trial contacts and locations

1

Loading...

Central trial contact

Hong Jian Wang, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems